Provided by Tiger Trade Technology Pte. Ltd.

Carpenter Technology

492.38
+3.300.67%
Post-market: 494.482.10+0.43%19:58 EDT
Volume:615.77K
Turnover:303.42M
Market Cap:24.40B
PE:46.80
High:495.51
Open:493.18
Low:484.00
Close:489.08
52wk High:625.99
52wk Low:228.00
Shares:49.56M
Float Shares:48.15M
Volume Ratio:1.17
T/O Rate:1.28%
Dividend:0.80
Dividend Rate:0.16%
EPS(TTM):10.52
EPS(LYR):10.52
ROE:25.75%
ROA:11.87%
PB:10.95
PE(LYR):46.80

Loading ...

Poolbeg Pharma Begins POLB 001 Trial, Targets Major CRS Market Opportunity

TIPRANKS
·
Jul 13

Is Carpenter Technology (CRS) Fully Valued Following Its Russell Index Removals?

Simply Wall St.
·
Jul 10

Carpenter Tech is Maintained at Positive by Susquehanna

Dow Jones
·
Jul 10

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

GlobeNewswire
·
Jul 07

Carpenter Technology Announces Conference Call and Webcast

GlobeNewswire
·
Jul 01

Carpenter Tech is Maintained at Overweight by Keybanc

Dow Jones
·
Jun 30

Analysts’ Top Industrial Goods Picks: Carpenter Technology (CRS), AeroVironment (AVAV)

TIPRANKS
·
Jun 30

Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development

GlobeNewswire
·
Jun 25

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

GlobeNewswire
·
Jun 14

Movement Alert|Carpenter Technology Rises 5.01% in Regular Trading, Trading at $548.98

Market Focus
·
Jun 11

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 11

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

GlobeNewswire
·
Jun 11

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

GlobeNewswire
·
Jun 11

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

GlobeNewswire
·
Jun 10

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

GlobeNewswire
·
Jun 09

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

GlobeNewswire
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

GlobeNewswire
·
Jun 08

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

GlobeNewswire
·
Jun 06

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

GlobeNewswire
·
Jun 04